Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Genmab (GMAB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,919.0 -53.0    -2.69%
- Real-time Data. Currency in DKK ( Disclaimer )
Type:  Equity
Market:  Denmark
ISIN:  DK0010272202 
S/N:  66122964
  • Volume: 117,455
  • Bid/Ask: 0.0 / 0.0
  • Day's Range: 1,916.0 - 1,983.5
Genmab 1,919.0 -53.0 -2.69%

Genmab Company Profile

 
Get an in-depth profile of Genmab, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

2132

Equity Type

ORD

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Contact Information

Address Carl Jacobsens Vej 30 Valby
Copenhagen, 2500
Denmark
Phone 45 70 20 27 28
Fax -

Top Executives

Name Age Since Title
Anders Gersel Pedersen 73 2003 Non-Independent Director
Deirdre P. Connelly 63 2017 Independent Chairman of the Board
Paolo Paoletti 73 2015 Independent Director
Pernille Erenbjerg 57 2015 Independent Deputy Chairman
Rolf Karl-Heinz Hoffmann 65 2016 Independent Director
Mijke Zachariasse 50 2019 Senior Director, Head of Antibody Research Materials & Non-Independent Director
Takahiro Hamatani 49 2022 Senior Director of Finance Japan & Non-Independent Director
Elizabeth G. O'Farrell 59 2022 Independent Director
Martin Schultz 48 2022 Senior Director of Clinical Operations & Non-Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GMAB Comments

Write your thoughts about Genmab
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mark Marriott
Mark Marriott Oct 27, 2021 7:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this stock worths buying for the long term?
The Note
TheNote Jul 26, 2021 11:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Target 3620 .. medium/long.Daily chart: https://invst.ly/vjgx1 Weekly chart: https://invst.ly/vjgxu
The Note
TheNote Jul 26, 2021 11:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Cup with handle - emminent !!!https://www.proinvestor.com/boards/95471Translate from that site (from danish) into english.
BumHunters Archer
JohnJenga Mar 17, 2021 7:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NBI might roll over. Risky now
BumHunters Archer
JohnJenga Mar 07, 2021 1:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1992 indicative price vs 1901 close dk and 1970 close us
BumHunters Archer
JohnJenga Mar 07, 2021 1:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2200 this week possible, imo
BumHunters Archer
JohnJenga Mar 04, 2021 5:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
nice correction - but have more or less only removed dec7jan baboon buys
Martin Lynge
Martin Lynge Mar 04, 2021 5:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
You mean since June last year.. .. Giant sell out...
Martin Lynge
Martin Lynge Jun 27, 2019 2:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
US 1st line approval this evening... 1200+ tomorrow?
Michael Almskov
Michael Almskov Jun 27, 2019 2:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://oasm.finanstilsynet.dk/dk/vismeddelelse.aspx?aid=f7f1738b-beb1-47b2-a9dc-ab402ccd42e9
Michael Almskov
Michael Almskov Jun 19, 2019 3:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Blackrock now owns 5% of the shares in genmab
Martin Lynge
Martin Lynge Feb 25, 2019 9:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Interesting to see, if we go beyond 1120 this time...
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email